Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections June 3, 2022 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... May 13, 2019 “Nothing about us without us”: Why we’re working in partnership with... March 10, 2023 NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 Load more HOT NEWS 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... Flame of Hope Awards: Celebrating our volunteers Black Patients Are More Likely to Die of Cancer—Here’s How One... FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable...
